Did advice on the prescription of sodium valproate reduce prescriptions to women? An observational study in three European countries between 2007 and 2016

Rachel Charlton, Christine Damase-Michel, Caroline Hurault-Delarue, Rosa Gini, Maria Loane, Anna Pierini, Aurora Puccini, Amanda Neville, Julia Snowball, Joan Morris, on behalf of the EUROmediSAFE Consortium

Research output: Contribution to journalArticle

7 Downloads (Pure)

Abstract

Objectives
In November 2014, the CMDh (a regulatory body representing EU Member States) advised doctors not to prescribe sodium valproate for epilepsy or bipolar disorder in preg nant women, in women who can become pregnant, or in girls unless other treatments are ineffective or not tolerated. This study aimed to determine if this warning led to changes in prescription patterns.

Design and setting
Cohort of 5.4 million women aged between 10 and 50 years identified in electronic health care data from United Kingdom, France, and Italy (2007–2016).

Main outcome measures
Anti‐epileptic drug (AED) prescriptions.

Results
The prevalence of women receiving AED prescriptions in 2016 varied from 12.2 per 1000 to 29 per 1000 in the four regions. The incidence of prescribing any AED (excluding clonazepam, gabapentin, and pregabalin) fell each year on average by 7.5% (95% CI, 7.0%‐8.0%; Emilia Romagna), 9.6% (8.3%‐11.0%; France), 7.1% (6.7%‐7.6%; Tuscany), and 0.4% (0.2%‐1.0%; United Kingdom). The relative odds of prescribing sodium valproate rather than any other AED decreased more after 2014 compared with before the end of 2014 in France (OR = 0.77; 95% CI, 0.60‐0.98), Tuscany (0.81; 0.76‐0.86), Emilia Romagna (0.83; 0.76‐0.90), and the United Kingdom (0.92; 0.80‐1.06; not statistically significant).

Conclusions
There is evidence that the CMDh warning did lead to changes in prescription patterns of sodium valproate in women of childbearing age. There were considerable differences in prescribing practice amongst regions of Europe.
Original languageEnglish
JournalPharmacoepidemiology and Drug Safety
Early online date26 Aug 2019
DOIs
Publication statusE-pub ahead of print - 26 Aug 2019

Keywords

  • antiepileptic medications
  • epidemiology
  • health care databases
  • sodium valproate

ASJC Scopus subject areas

  • Epidemiology
  • Pharmacology (medical)

Cite this

Did advice on the prescription of sodium valproate reduce prescriptions to women? An observational study in three European countries between 2007 and 2016. / Charlton, Rachel; Damase-Michel, Christine; Hurault-Delarue, Caroline ; Gini, Rosa; Loane, Maria; Pierini, Anna ; Puccini, Aurora; Neville, Amanda; Snowball, Julia; Morris, Joan; EUROmediSAFE Consortium, on behalf of the .

In: Pharmacoepidemiology and Drug Safety, 26.08.2019.

Research output: Contribution to journalArticle

Charlton, Rachel ; Damase-Michel, Christine ; Hurault-Delarue, Caroline ; Gini, Rosa ; Loane, Maria ; Pierini, Anna ; Puccini, Aurora ; Neville, Amanda ; Snowball, Julia ; Morris, Joan ; EUROmediSAFE Consortium, on behalf of the . / Did advice on the prescription of sodium valproate reduce prescriptions to women? An observational study in three European countries between 2007 and 2016. In: Pharmacoepidemiology and Drug Safety. 2019.
@article{6257ba77170a466e84ba480e6babd8d2,
title = "Did advice on the prescription of sodium valproate reduce prescriptions to women? An observational study in three European countries between 2007 and 2016",
abstract = "ObjectivesIn November 2014, the CMDh (a regulatory body representing EU Member States) advised doctors not to prescribe sodium valproate for epilepsy or bipolar disorder in preg nant women, in women who can become pregnant, or in girls unless other treatments are ineffective or not tolerated. This study aimed to determine if this warning led to changes in prescription patterns.Design and settingCohort of 5.4 million women aged between 10 and 50 years identified in electronic health care data from United Kingdom, France, and Italy (2007–2016).Main outcome measuresAnti‐epileptic drug (AED) prescriptions.ResultsThe prevalence of women receiving AED prescriptions in 2016 varied from 12.2 per 1000 to 29 per 1000 in the four regions. The incidence of prescribing any AED (excluding clonazepam, gabapentin, and pregabalin) fell each year on average by 7.5{\%} (95{\%} CI, 7.0{\%}‐8.0{\%}; Emilia Romagna), 9.6{\%} (8.3{\%}‐11.0{\%}; France), 7.1{\%} (6.7{\%}‐7.6{\%}; Tuscany), and 0.4{\%} (0.2{\%}‐1.0{\%}; United Kingdom). The relative odds of prescribing sodium valproate rather than any other AED decreased more after 2014 compared with before the end of 2014 in France (OR = 0.77; 95{\%} CI, 0.60‐0.98), Tuscany (0.81; 0.76‐0.86), Emilia Romagna (0.83; 0.76‐0.90), and the United Kingdom (0.92; 0.80‐1.06; not statistically significant).ConclusionsThere is evidence that the CMDh warning did lead to changes in prescription patterns of sodium valproate in women of childbearing age. There were considerable differences in prescribing practice amongst regions of Europe.",
keywords = "antiepileptic medications, epidemiology, health care databases, sodium valproate",
author = "Rachel Charlton and Christine Damase-Michel and Caroline Hurault-Delarue and Rosa Gini and Maria Loane and Anna Pierini and Aurora Puccini and Amanda Neville and Julia Snowball and Joan Morris and {EUROmediSAFE Consortium}, {on behalf of the}",
year = "2019",
month = "8",
day = "26",
doi = "10.1002/pds.4881",
language = "English",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Did advice on the prescription of sodium valproate reduce prescriptions to women? An observational study in three European countries between 2007 and 2016

AU - Charlton, Rachel

AU - Damase-Michel, Christine

AU - Hurault-Delarue, Caroline

AU - Gini, Rosa

AU - Loane, Maria

AU - Pierini, Anna

AU - Puccini, Aurora

AU - Neville, Amanda

AU - Snowball, Julia

AU - Morris, Joan

AU - EUROmediSAFE Consortium, on behalf of the

PY - 2019/8/26

Y1 - 2019/8/26

N2 - ObjectivesIn November 2014, the CMDh (a regulatory body representing EU Member States) advised doctors not to prescribe sodium valproate for epilepsy or bipolar disorder in preg nant women, in women who can become pregnant, or in girls unless other treatments are ineffective or not tolerated. This study aimed to determine if this warning led to changes in prescription patterns.Design and settingCohort of 5.4 million women aged between 10 and 50 years identified in electronic health care data from United Kingdom, France, and Italy (2007–2016).Main outcome measuresAnti‐epileptic drug (AED) prescriptions.ResultsThe prevalence of women receiving AED prescriptions in 2016 varied from 12.2 per 1000 to 29 per 1000 in the four regions. The incidence of prescribing any AED (excluding clonazepam, gabapentin, and pregabalin) fell each year on average by 7.5% (95% CI, 7.0%‐8.0%; Emilia Romagna), 9.6% (8.3%‐11.0%; France), 7.1% (6.7%‐7.6%; Tuscany), and 0.4% (0.2%‐1.0%; United Kingdom). The relative odds of prescribing sodium valproate rather than any other AED decreased more after 2014 compared with before the end of 2014 in France (OR = 0.77; 95% CI, 0.60‐0.98), Tuscany (0.81; 0.76‐0.86), Emilia Romagna (0.83; 0.76‐0.90), and the United Kingdom (0.92; 0.80‐1.06; not statistically significant).ConclusionsThere is evidence that the CMDh warning did lead to changes in prescription patterns of sodium valproate in women of childbearing age. There were considerable differences in prescribing practice amongst regions of Europe.

AB - ObjectivesIn November 2014, the CMDh (a regulatory body representing EU Member States) advised doctors not to prescribe sodium valproate for epilepsy or bipolar disorder in preg nant women, in women who can become pregnant, or in girls unless other treatments are ineffective or not tolerated. This study aimed to determine if this warning led to changes in prescription patterns.Design and settingCohort of 5.4 million women aged between 10 and 50 years identified in electronic health care data from United Kingdom, France, and Italy (2007–2016).Main outcome measuresAnti‐epileptic drug (AED) prescriptions.ResultsThe prevalence of women receiving AED prescriptions in 2016 varied from 12.2 per 1000 to 29 per 1000 in the four regions. The incidence of prescribing any AED (excluding clonazepam, gabapentin, and pregabalin) fell each year on average by 7.5% (95% CI, 7.0%‐8.0%; Emilia Romagna), 9.6% (8.3%‐11.0%; France), 7.1% (6.7%‐7.6%; Tuscany), and 0.4% (0.2%‐1.0%; United Kingdom). The relative odds of prescribing sodium valproate rather than any other AED decreased more after 2014 compared with before the end of 2014 in France (OR = 0.77; 95% CI, 0.60‐0.98), Tuscany (0.81; 0.76‐0.86), Emilia Romagna (0.83; 0.76‐0.90), and the United Kingdom (0.92; 0.80‐1.06; not statistically significant).ConclusionsThere is evidence that the CMDh warning did lead to changes in prescription patterns of sodium valproate in women of childbearing age. There were considerable differences in prescribing practice amongst regions of Europe.

KW - antiepileptic medications

KW - epidemiology

KW - health care databases

KW - sodium valproate

UR - http://www.scopus.com/inward/record.url?scp=85071622970&partnerID=8YFLogxK

U2 - 10.1002/pds.4881

DO - 10.1002/pds.4881

M3 - Article

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

ER -